
Pfizer’s Paxlovid is a combination of a new molecule developed specifically to disable SARS-CoV-2 and ritonavir, an HIV medication that helps slow the breakdown of the coronavirus-specific drug. The company has begun manufacturing and packaging the drug in factories in Ireland, Germany and Italy and has projected having 180,000 pill packs available by the end of the year and 50 million in 2022.
The Washington Post: Breaking News, World, US, DC News and Analysis
0 Comments